CD4 and neoplasm: Tumours treated with low-dose decitabine also had greater CD4+ and CD8+ PD-1-positive tumour-infiltrating T-lymphocytes in the tumour microenvironment compared to the untreated tumours, suggesting an enhanced response to PD-1 inhibition [41].